Health & Bio

FDA Vyvgart seronegative gMG approval timeline set

argenx efgartigimod alfa-fcab PDUFA May 10 date, expands AChR-antibody-negative myasthenia gravis. Home-start option hoped.

Primary sources · 1
Cardiology Advisor
← View the full 2026-05-14 (Thu) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →